Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-derived escape-associated neoantigen could be exploited...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0057781c39ce43a79a6659f6e847a415 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0057781c39ce43a79a6659f6e847a415 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0057781c39ce43a79a6659f6e847a4152021-12-02T13:24:23ZOncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy10.1038/s41467-021-22115-12041-1723https://doaj.org/article/0057781c39ce43a79a6659f6e847a4152021-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22115-1https://doaj.org/toc/2041-1723Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-derived escape-associated neoantigen could be exploited for immunotherapy against treatment-resistant tumors.Timothy KottkeJason TonneLaura EvginChristopher B. DriscollJacob van VlotenVictoria A. JenningsAmanda L. HuffBrady ZellJill M. ThompsonPhonphimon WongthidaJose PulidoMatthew R. SchuelkeAdel SamsonPeter SelbyElizabeth IlettMark McNivenLewis R. RobertsMitesh J. BoradHardev PandhaKevin HarringtonAlan MelcherRichard G. VileNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Timothy Kottke Jason Tonne Laura Evgin Christopher B. Driscoll Jacob van Vloten Victoria A. Jennings Amanda L. Huff Brady Zell Jill M. Thompson Phonphimon Wongthida Jose Pulido Matthew R. Schuelke Adel Samson Peter Selby Elizabeth Ilett Mark McNiven Lewis R. Roberts Mitesh J. Borad Hardev Pandha Kevin Harrington Alan Melcher Richard G. Vile Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| description |
Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-derived escape-associated neoantigen could be exploited for immunotherapy against treatment-resistant tumors. |
| format |
article |
| author |
Timothy Kottke Jason Tonne Laura Evgin Christopher B. Driscoll Jacob van Vloten Victoria A. Jennings Amanda L. Huff Brady Zell Jill M. Thompson Phonphimon Wongthida Jose Pulido Matthew R. Schuelke Adel Samson Peter Selby Elizabeth Ilett Mark McNiven Lewis R. Roberts Mitesh J. Borad Hardev Pandha Kevin Harrington Alan Melcher Richard G. Vile |
| author_facet |
Timothy Kottke Jason Tonne Laura Evgin Christopher B. Driscoll Jacob van Vloten Victoria A. Jennings Amanda L. Huff Brady Zell Jill M. Thompson Phonphimon Wongthida Jose Pulido Matthew R. Schuelke Adel Samson Peter Selby Elizabeth Ilett Mark McNiven Lewis R. Roberts Mitesh J. Borad Hardev Pandha Kevin Harrington Alan Melcher Richard G. Vile |
| author_sort |
Timothy Kottke |
| title |
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| title_short |
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| title_full |
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| title_fullStr |
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| title_full_unstemmed |
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy |
| title_sort |
oncolytic virotherapy induced csde1 neo-antigenesis restricts vsv replication but can be targeted by immunotherapy |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/0057781c39ce43a79a6659f6e847a415 |
| work_keys_str_mv |
AT timothykottke oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT jasontonne oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT lauraevgin oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT christopherbdriscoll oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT jacobvanvloten oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT victoriaajennings oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT amandalhuff oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT bradyzell oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT jillmthompson oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT phonphimonwongthida oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT josepulido oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT matthewrschuelke oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT adelsamson oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT peterselby oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT elizabethilett oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT markmcniven oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT lewisrroberts oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT miteshjborad oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT hardevpandha oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT kevinharrington oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT alanmelcher oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy AT richardgvile oncolyticvirotherapyinducedcsde1neoantigenesisrestrictsvsvreplicationbutcanbetargetedbyimmunotherapy |
| _version_ |
1718393071051210752 |